Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Cerium oxide nanoparticles attenuate monocrotaline induced right ventricular hypertrophy following pulmonary arterial hypertension.

Authors
Kolli-MB; Manne-NDPK; Para-R; Nalabotu-SK; Nandyala-G; Shokuhfar-T; He-K; Hamlekhan-A; Ma-JY; Wehner-PS; Dornon-L; Arvapalli-R; Rice-KM; Blough-ER
Source
Biomaterials 2014 Dec; 35(37):9951-9962
NIOSHTIC No.
20045149
Abstract
Cerium oxide (CeO2) nanoparticles have been posited to exhibit potent anti-oxidant activity which may allow for the use of these materials in biomedical applications. Herein, we investigate whether CeO2 nanoparticle administration can diminish right ventricular (RV) hypertrophy following four weeks of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH). Male Sprague Dawley rats were randomly divided into three groups: control, MCT only (60 mg/kg), or MCT + CeO2 nanoparticle treatment (60 mg/kg; 0.1 mg/kg). Compared to the control group, the RV weight to body weight ratio was 45% and 22% higher in the MCT and MCT + CeO2 groups, respectively (p < 0.05). Doppler echocardiography demonstrated that CeO2 nanoparticle treatment attenuated monocrotaline-induced changes in pulmonary flow and RV wall thickness. Paralleling these changes in cardiac function, CeO2 nanoparticle treatment also diminished MCT-induced increases in right ventricular (RV) cardiomyocyte cross sectional area, -myosin heavy chain, fibronectin expression, protein nitrosylation, protein carbonylation and cardiac superoxide levels. These changes with treatment were accompanied by a decrease in the ratio of Bax/Bcl2, diminished caspase-3 activation and reduction in serum inflammatory markers. Taken together, these data suggest that CeO2 nanoparticle administration may attenuate the hypertrophic response of the heart following PAH.
Keywords
Nanotechnology; Cerium-compounds; Antioxidants; Pulmonary-function; Pulmonary-system; Pulmonary-system-disorders; Animals; Laboratory-animals; Cardiopulmonary-system; Cardiopulmonary-function; Heart; Proteins; Hypertension; Author Keywords: Cerium oxide nanoparticles; Monocrotaline; Pulmonary arterial hypertension; Right ventricular hypertrophy
Contact
Eric R. Blough, Center for Diagnostic Nanosystems, Room 241R, Robert C. Byrd Biotechnology Science Center Building, Department of Pharmaceutical Science and Research, 1700 3rd Ave., Marshall University, Huntington, WV 25755-1090
CODEN
BIMADU
CAS No.
1306-38-3
Publication Date
20141201
Document Type
Journal Article
Email Address
blough@marshall.edu
Fiscal Year
2015
NTIS Accession No.
NTIS Price
Identifying No.
M102014
Issue of Publication
37
ISSN
0142-9612
NIOSH Division
HELD
Priority Area
Manufacturing
Source Name
Biomaterials
State
WV; MI
TOP